ATRS - Antares Pharma - Why It's A $4 Stock (And Might Remain So)
- Antares Pharma operates in crowded markets with relatively low barriers to entry and intense competition.
- Their flagship product, XYOSTED, grew significantly in 2019 and 2020 but competitors may enter the market as soon as October 2021.
- Their business model forces them to be secretive about development products, but this makes it impossible to estimate future growth.
- The track record of ATRS and their partners for regulatory approvals has been poor.
- Overall, too much uncertainty limits share price appreciation.
For further details see:
Antares Pharma - Why It's A $4 Stock (And Might Remain So)